Company Overview
Koninklijke Philips N.V. functions as a health technology company with operations spanning North America, Greater China, and international markets, providing diagnostic imaging solutions and ultrasound services through its Diagnosis & Treatment, Connected Care, and Personal Health segments. The enterprise operates within the Healthcare sector, specifically the Medical Devices industry, positioning it as a critical supplier of essential medical infrastructure and technology for global healthcare systems. This significant entity holds a market capitalization of $25.67B and generated annual revenue of $17.83B, supporting a global workforce of 61,085 employees. The magnitude of these financial figures indicates that the company maintains a substantial footprint in the global medical technology landscape, commanding a valuation that reflects its established role in delivering complex diagnostic and treatment equipment to diverse healthcare providers.
Financial Health
The company reported a trailing twelve-month revenue of $17.83B with a corresponding net income of $899.00M and EBITDA of $2.02B, while the disparity between the total revenue and net income highlights a cost structure where operating expenses, including taxes and interest, consume approximately 95% of gross earnings before reaching the bottom line. Free cash flow stands at $453.00M, which represents the cash remaining after capital expenditures and operational costs, signaling a moderate level of financial flexibility for the company to fund ongoing operations or strategic initiatives without relying heavily on external financing. Profitability analysis reveals a gross margin of 45.2%, an operating margin of 10.7%, and a profit margin of 5.0%, indicating that while the core business model retains nearly half of revenue after the cost of goods sold, significant operational costs reduce the final profit to roughly half a percent of sales. The balance sheet shows total cash holdings of $2.79B against total debt of $8.09B, resulting in a debt-to-equity ratio of 73.57, which suggests the company utilizes a leveraged approach to finance its assets rather than maintaining a conservative, cash-heavy stance. Liquidity is supported by a current ratio of 1.32, indicating that the company holds sufficient current assets to cover its short-term liabilities, though the buffer is relatively tight for an industry with high working capital requirements. Return on equity is recorded at 7.8% and return on assets at 3.2%, metrics that reveal management's effectiveness in generating profits from shareholder capital and total assets, respectively, with the lower ROA reflecting the capital-intensive nature of the medical device manufacturing business.
Valuation Assessment
Valuation metrics show a trailing P/E ratio of 25.03 and a forward P/E of 12.84, implying that the market expects earnings to grow significantly in the coming years to justify the lower forward multiple relative to the current price. The price-to-book ratio is 2.01, indicating that the market values the company at more than double its net asset book value, which suggests investors are pricing in intangible assets, brand value, or future growth potential beyond the tangible balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.44 and an EV/EBITDA of 15.28, suggesting that the company trades at a premium relative to its sales and earnings before interest, taxes, depreciation, and amortization compared to historical averages for similar capital-intensive firms. The stock has traded between a 52-week high of $33.44 and a 52-week low of $21.48, and without a specific current price provided in the facts, the valuation range defines the volatility envelope within which the stock has moved over the past year. The beta value is 0.94, indicating that the stock's price volatility moves slightly less than the broader market, suggesting a marginally lower sensitivity to general market fluctuations compared to the S&P 500 index.
Growth & Income
Revenue growth for the trailing twelve months stands at 1.1%, while earnings growth is listed as N/A, indicating that the company has maintained a stable revenue trajectory but that specific year-over-year earnings expansion data is not currently available for calculation or reporting. Given the lack of explicit earnings growth figures, it is not possible to determine if earnings are growing faster or slower than revenue, but the modest 1.1% revenue increase suggests a mature market environment where organic expansion is incremental rather than explosive. As a dividend payer, the company offers a dividend yield of 3.8% with a payout ratio of 91.7%, which means that nearly all of the net income is distributed to shareholders, leaving limited retained earnings for internal reinvestment and potentially limiting the capacity to sustain the dividend if earnings were to decline. The overall growth and income profile presents a scenario of a mature, low-growth asset that compensates investors primarily through a high-yield dividend rather than through capital appreciation or rapid revenue expansion.